ANNUAL REPORT
OF THE WRAIR PSYCHOPHARMACOLOGY STUDY GROUP

SECTION 1   CURRENT CONCEPTS IN THE USE OF DRUGS
             FOR THE MODIFICATION OF BEHAVIOR

                  This section would contain chapters on
philosophic issues such as the evidence for and against drugs as
"magic bullets", issues of current research methodologies, and
perceived areas of needed research.

SECTION 2   PHARMACOLOGIC ENHANCEMENT OF MILITARY PERFORMANCE

             OVERVIEW CHAPTER
                     enhancement of normal performance
                     vs. degredation countermeasures,
                     task validation of research
                     variables, etc.

             REVIEW OF SPECIFIC DRUGS

             RECOMMENDATIONS FOR FUTURE RESEARCH

SECTION 3   CASUALTY MANAGEMENT

             OVERVIEW CHAPTER
                     types of casualties, goals
                     of treatment, ethical issues etc.

             REVIEW OF SPECIFIC DRUGS

             RECOMMENDATIONS FOR FUTURE RESEARCH

SECTION 4   THREAT ASSESSMENT AND DEFENSE

             POTENTIAL OFFENSIVE USES OF PSYCHOACTIVE
             CHEMICALS
                     to include covert, pre-conflict, and
                     terrorist operations as well as full
                     scale and limited war

             REVIEW OF SPECIFIC DRUGS

             DEFENSE AND TREATMENT

             RECOMMENDATIONS FOR FURTHER RESEARCH

SECTION 5   BEHAVIORAL EFFECTS OF OTHER DRUGS
                     e.g. anti-malarial drugs, chem
                     defense compounds etc.

TO: PSYCHOPHARM STUDY GROUP MEMBERS   FROM: VINCE O'DONNELL

SUBJECT: SUGGESTION FOR GROUP DOCUMENT   23 MARCH 1984

1.   I advocate that the Psychopharm Study Group produce an annual
document that would constitute a review of important areas within
the group's focus. The document would be written at a
professional level and would be distributed within the MRDC
community and to select organizations which might have a use for
it.   The document would serve as a source for other output of the
group, with select chapters modified and distributed to specific
audiences in the form of WRAIR reports, NP reports,
recommendations for funding, etc.   I would envision that the
Psychopharm Study Group would be the overall "author" with
individual members listed as authors for parts that they have
written.

2.   My idea for the organization of this document is detailed on
the following page.